DKN 01

Drug Profile

DKN 01

Alternative Names: DKN-01; LY-2812176

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Leap Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action DKK1 protein inhibitors; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Ovarian cancer
  • Phase I/II Gastric cancer; Hepatocellular carcinoma; Oesophageal cancer
  • Phase I Biliary cancer; Multiple myeloma; Non-small cell lung cancer

Most Recent Events

  • 21 Jun 2018 Phase-I/II clinical trials in Hepatocellular carcinoma (Combination therapy, Late-stage disease) in Germany (IV) (EudraCT2017-002468-41)
  • 21 Jun 2018 Phase-I/II clinical trials in Hepatocellular carcinoma (Monotherapy, Late-stage disease) in Germany (IV) (EudraCT2017-002468-41)
  • 16 Apr 2018 Efficacy data from a phase I/II trial in Oesophageal cancer presented at the Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top